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ABSTRACT
Objective Subcutaneous (SC) and intravenous
formulations of tocilizumab (TCZ) are available for the
treatment of patients with rheumatoid arthritis (RA),
based on the efﬁcacy and safety observed in clinical
trials. Anti-TCZ antibody development and its impact on
safety and efﬁcacy were evaluated in adult patients with
RA treated with intravenous TCZ (TCZ-IV) or TCZ-SC as
monotherapy or in combination with conventional
synthetic disease-modifying antirheumatic drugs
(csDMARDs).
Methods Data from 5 TCZ-SC and 8 TCZ-IV phase III
clinical trials and 1 TCZ-IV clinical pharmacology safety
study (>50 000 samples) were pooled to assess the
immunogenicity proﬁle of TCZ-SC and TCZ-IV (8974
total patients). The analysis included antidrug antibody
(ADA) measurement following TCZ-SC or TCZ-IV
treatment as monotherapy or in combination with
csDMARDs, after dosing interruptions or in TCZ-washout
samples, and the correlation of ADAs with clinical
response, adverse events or pharmacokinetics (PK).
Results The proportion of patients who developed
ADAs following TCZ-SC or TCZ-IV treatment was 1.5%
and 1.2%, respectively. ADA development was also
comparable between patients who received TCZ
monotherapy and those who received concomitant
csDMARDs (0.7–2.0%). ADA development did not
correlate with PK or safety events, including anaphylaxis,
hypersensitivity or injection-site reactions, and no
patients who developed ADAs had loss of efﬁcacy.
Conclusions The immunogenicity risk of TCZ-SC and
TCZ-IV treatment was low, either as monotherapy or in
combination with csDMARDs. Anti-TCZ antibodies
developed among the small proportion of patients had
no evident impact on PK, efﬁcacy or safety.
INTRODUCTION
For patients with rheumatoid arthritis (RA) who do
not respond to or are intolerant of conventional
synthetic disease-modifying antirheumatic drugs
(csDMARDs), biologic DMARDs (bDMARDs)
are recommended.1 Often, a bDMARD and
≥1 csDMARD are used in combination, but
bDMARDs can also be used as monotherapy. The
currently approved bDMARDs include antitumour
necrosis factor-α agents (aTNFs), anti-interleukin 6
receptor (IL-6R) therapy, anti-CD20 B cell targeted
therapy and T cell co-stimulation inhibition. One
safety concern of bDMARDs is the development of
antidrug antibodies (ADAs).2 Multiple factors may
contribute to ADA development, including struc-
ture and idiotype,3 route of administration,3 mech-
anism of action,4 concomitant csDMARD use,5 6
disease activity,7 genetic status,3 8 patient immuno-
competence,3 treatment duration,3 the disease
itself9 and drug dose/frequency.8 ADAs can lead to
loss of efﬁcacy10 and/or immune-mediated adverse
reactions, including IgE-mediated or non-IgE-
mediated events.11
Tocilizumab (TCZ) is a humanised monoclonal
antibody (mAb) of the IgG1 subclass that blocks
IL-6 binding to the membrane-bound and soluble
IL-6R, consequently inhibiting IL-6 activity. TCZ is
approved for adult RA (as intravenous or subcuta-
neous (SC) formulations) and as intravenous for
systemic-course and polyarticular-course juvenile
idiopathic arthritis and Castleman disease ( Japan
only).12 TCZ has demonstrated efﬁcacy and a well
characterised safety proﬁle as monotherapy or in
combination with csDMARDs.13–19
This study addresses important clinical and scien-
tiﬁc questions: Is a therapeutic antibody by SC
administration more immunogenic compared with
intravenous administration? Is the immunogenic risk
of TCZ monotherapy similar to that of co-therapy
with methotrexate (MTX)? Here, the immunogen-
icity of TCZ is assessed in different clinical settings
—ADA development following TCZ administration
as SC or intravenous formulations as monotherapy
or in combination with csDMARDs, after dosing
interruptions and in TCZ-washout samples—as well
as its correlation with adverse events (AEs), clinical
response and pharmacokinetics (PK). Data were
derived from ﬁve TCZ-SC and nine intravenous
TCZ (TCZ-IV) RA trials plus their long-term exten-
sions: SUMMACTA,20 21 BREVACTA,22 23 the
TCZ-SC long-term extension rollover study of US
patients from BREVACTA and SUMMACTA,24
MUSASHI (Multi-Center Double-Blind Study of
Tocilizumab Subcutaneous Injection in Patients
Having Rheumatoid Arthritis to Verify
Noninferiority Against Intravenous Infusion),25 26
FUNCTION,27 AMBITION (Actemra vs
Methotrexate Double-Blind Investigative Trial in
Monotherapy),15 TOWARD (Tocilizumab in
Combination With Traditional DMARD
Therapy),17 OPTION (Tocilizumab Pivotal Trial in
Methotrexate Inadequate Responders),13 LITHE
(Tocilizumab Safety and the Prevention of Structural
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Joint Damage),14 RADIATE (Research on Actemra Determining
Efﬁcacy After Anti-TNF Failures),16 TOZURA global umbrella
study (interim analysis) and a clinical pharmacology study.28
PATIENTS AND METHODS
Study designs
The study designs of the TCZ trials are summarised (see online
supplementary table S1).13–17 20 22 24 25 27
Sampling
Blood samples for ADA detection and PK analysis were col-
lected at baseline and regularly predose (TCZ trough level)
throughout the studies and at the study completion or early
withdrawal visit. Furthermore, patients who withdrew due to
hypersensitivity reactions in ﬁve of the studies had additional
samples for ADAs collected at the time of the event and at least
4–8 weeks after the last treatment.20 22 24 27 To minimise poten-
tial TCZ interference in the immunogenicity assay, in the
TCZ-IV versus TCZ-SC study, TCZ-washout samples (at least 4
weeks or 8 weeks after the last treatment, or predose samples
after treatment interruptions during the study) were
evaluated.20
Immunogenicity assessment strategy and assays
In all studies, consistent assay methodology was applied,29 and a
sequential testing strategy was adopted (ﬁgure 1). All samples
were initially screened for antibodies, and positive samples were
analysed by a conﬁrmation assay for speciﬁcity. Characterisation
of any samples with conﬁrmed anti-TCZ antibodies was per-
formed to detect neutralising potential and IgE isotype. In three
studies, an IgE assay was also conducted in patients who with-
drew because of hypersensitivity reactions, regardless of their
conﬁrmation assay status.20 22 24 27 The IgE assay was not per-
formed in the TCZ-IV studies consistently; therefore, results
were not available. Clinical AEs and efﬁcacy measures were eval-
uated in association with ADA development.
The screening assay employed a bridging ELISA and used bio-
tinylated TCZ from different labelling preparations immobilised
on streptavidin-coated microtitre plates. Anti-TCZ antibodies
form a complex of TCZ-biotin/anti-TCZ antibody/TCZ-digoxi-
genin, captured by immobilised streptavidin and then detected
by an antidigoxigenin-peroxidase antibody (ﬁgure 2A). An assay
cut point was determined from serum samples from patients
with RA, containing various levels of rheumatoid factor in order
to minimise its interference. The conﬁrmation assay was con-
ducted the same as the screening assay except the preincubation
of test or control samples with digoxigenylated TCZ was
performed in parallel in the presence and absence of excess free
TCZ, which competes with digoxigenylated TCZ and biotiny-
lated TCZ for binding to anti-TCZ antibodies (ﬁgure 2B).
To detect neutralising potential of ADAs, an inhibition ELISA
was performed for all studies except the Japanese study (ﬁgure
2C). The neutralising assay evaluates whether anti-TCZ anti-
bodies competitively interfere with the binding of TCZ to
immobilised soluble IL-6R. Blocking the binding of TCZ to
IL-6R, resulting in a decrease in assay signal, is indicative that
anti-TCZ antibodies can neutralise the therapeutic effect of
TCZ. In the Japanese study, an antigen-binding fragment (Fab)
assay in a bridging ELISA format that can detect anti-TCZ anti-
bodies that bind to the Fab fragment of TCZ was applied as the
neutralising assay.25 26 IgE isotype antibodies were detected
using the ImmunoCAP assay system (Quest Diagnostics) (ﬁgure
2D).29 Anti-TCZ-IgE antibodies captured by immobilised TCZ
were detected by an antihuman IgE-speciﬁc antibody.
PK assay
TCZ serum concentrations were determined by ELISA. The
lower limit of quantitation was 100 ng/mL. The impact of ADAs
on PK was formally evaluated in three intravenous studies and
two SC studies.13 16 17 20 22
Analyses
In all studies except the Japanese study, hypersensitivity events
were conservatively deﬁned as all AEs (excluding injection-site
reactions (ISRs)) that occurred during or within 24 hours of an
infusion or injection and were not judged unrelated to
Figure 1 Tocilizumab (TCZ)
immunogenicity assessment strategy*.
*Blood samples were taken at baseline
(BL) and regularly prior to dosing
throughout the studies. q12w, every
12 weeks.
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treatment by the investigator; those events may or may not be
consistent with hypersensitivity clinically. Anaphylactic reactions
were events that occurred during or within 24 hours of an infu-
sion or injection and met Sampson criteria.30 Serious
hypersensitivity events were hypersensitivity events that were
also reported as serious AEs, and clinically signiﬁcant hypersen-
sitivity events were hypersensitivity events that led to study
withdrawal. ISRs were AEs occurring at the local injection
Figure 2 Anti-tocilizumab (anti-TCZ)
antibody assay. (A) The screening
assay employed bridging ELISAs and
used biotinylated TCZ from different
labelling preparations immobilised on
streptavidin-coated microtitre plates.
Bi, biotin; Dig, digoxigenin; SA-MTP,
streptavidin-coated microtitre plate;
POD, peroxidase. (B) For samples
positive from the screening assay, an
additional competitive displacement
step was used for the conﬁrmation
assay, where unlabelled TCZ inhibited
the formation of TCZ-Bi/anti-TCZ
antibody/TCZ-Dig complexes. (C) An
inhibition ELISA was adopted to detect
the neutralising potential of anti-TCZ
antibodies (whether anti-TCZ
antibodies competitively interfere with
the binding of TCZ to immobilised
soluble IL-6 receptor (sIL-6R)). (D) IgE
isotype antibodies were detected using
the ImmunoCAP assay system (Quest
Diagnostics).
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sites following SC administration. In the Japanese study, hyper-
sensitivity events were deﬁned as AEs (excluding ISRs) that
occurred during or within 24 hours of an infusion or injection
and were also judged to be a hypersensitivity event by the clin-
ical expert.25 26
Assay results were also evaluated for patients who met the cri-
teria for loss of efﬁcacy, deﬁned as those who withdrew from
the study prematurely due to insufﬁcient therapeutic response
after experiencing an American College of Rheumatology cri-
teria for 50% improvement or a European League Against
Rheumatism good response.
RESULTS
Patient population
The TCZ-SC all-exposure population consisted of 3099 patients
from the clinical trials, including 616 patients who received
TCZ-SC as monotherapy and 2483 who received TCZ-SC in
combination with csDMARDs (ﬁgure 3A). TCZ-SC treatment
was administered for up to 3.5 years. The TCZ-IV all-exposure
population consisted of 5875 patients, with 753 patients who
received TCZ-IV as monotherapy and 5122 who received
TCZ-IV in combination with csDMARDs (ﬁgure 3B). TCZ-IV
treatment was administered for up to 5 years.
Incidence of ADA development and effect on safety and
efﬁcacy following TCZ-SC or TCZ-IV all-exposure
Of the patients who received TCZ-SC or TCZ-IV and were
screened for ADAs (99.8% and 98.8%, respectively), the pro-
portion of patients who developed ADAs following either TCZ
treatment was low and comparable (1.5% (47 patients) and
1.2% (69 patients), respectively; table 1). Among the patients
who developed ADAs, 40 (85.1%) who received TCZ-SC and
54 (78.3%) who received TCZ-IV were also positive for the
neutralising assay. Of the patients who were screened for ADAs,
9 (0.3%) who received TCZ-SC developed IgE antibodies;
results for IgE antibodies were not available for TCZ-IV. In all
studies, most detected ADAs were transient and did not occur at
all time points (see online supplementary table S2).
Figure 3 Patient disposition.
Immunogenicity was assessed from the
clinical trials following treatment in
patients with rheumatoid arthritis.
(A) Treatment with subcutaneous
tocilizumab (TCZ-SC). Mono,
monotherapy; csDMARD, conventional
synthetic disease-modifying
antirheumatic drug; IR. inadequate
responder; aTNF, antitumour necrosis
factor-α agent; LTE, long-term
extension. (B) Treatment with
intravenous tocilizumab (TCZ-IV). MTX,
methotrexate.
*TOZURA is a multinational, open-
label, single-arm global umbrella study
comprising 11 protocols from different
countries/regions.
†There were a total of 217 patients
who received TCZ-SC treatment in the
long-term extension (LTE) rollover
study, including 55 patients who
switched from TCZ-IV (in SUMMACTA)
to TCZ-SC for the LTE rollover period.
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Among the all-exposure safety populations, no patients who
received TCZ-SC experienced anaphylaxis, whereas 10 patients
(0.2%) who received TCZ-IV had anaphylaxis (table 1).
Clinically signiﬁcant hypersensitivity (leading to study with-
drawal) occurred in 31 patients (1.0%) who received TCZ-SC
and in 91 patients (1.5%) who received TCZ-IV; 10 patients
(0.3%) in the TCZ-SC group and 51 (0.9%) in the TCZ-IV
group had serious hypersensitivity (hypersensitivity events
meeting seriousness criteria). Of the 47 patients who received
TCZ-SC and developed ADAs, 1 (2.1%) experienced clinically
signiﬁcant hypersensitivity, but none had serious hypersensiti-
vity. Of the 69 patients who received TCZ-IV and developed
ADAs, 5 (7.2%) experienced anaphylaxis, 10 (14.5%) had clin-
ically signiﬁcant hypersensitivity, and 6 (8.7%) had serious
hypersensitivity, including the 5 patients with anaphylaxis.
Among the patients who received TCZ-SC, a total of 310
(10.0%) experienced ISRs. Of the 47 patients who received
TCZ-SC and developed ADAs, 4 (8.5%) experienced ISRs; all
events resolved without sequelae.
Among all patients who developed ADAs with neutralising
potential following TCZ treatment, none experienced loss of
efﬁcacy, regardless of formulation (table 1).
Incidence of ADA development and effect on safety
and efﬁcacy following TCZ monotherapy or in combination
with csDMARDs
The overall incidence of ADA development was low in the 1360
patients treated with TCZ monotherapy (intravenous: 0.7%;
SC: 2.0%) and the 7540 patients treated with TCZ+
csDMARDs (intravenous: 1.3%; SC: 1.4%), regardless of for-
mulation (table 2).
Among the safety population, the incidences of hypersensitiv-
ity events were consistent between patients who received TCZ
monotherapy or TCZ + csDMARDs (table 2). No patients
experienced anaphylaxis with TCZ-SC compared with 1 patient
(0.1%) who received TCZ-IV monotherapy and 9 patients
(0.2%) who received TCZ-IV+csDMARDs. Clinically signiﬁcant
hypersensitivity occurred in 6 patients (1.0%) who received
TCZ-SC monotherapy and in 25 patients (1.0%) who received
TCZ-SC+csDMARDs. Serious hypersensitivity occurred in one
patient (0.2%) in the TCZ-SC monotherapy group and in nine
patients (0.4%) in the TCZ-SC+csDMARDs group. Twelve
patients (1.6%) who received TCZ-IV monotherapy and 79
(1.5%) who received TCZ-IV+csDMARDs had clinically signiﬁ-
cant hypersensitivity events. Nine patients (1.2%) who received
TCZ-IV monotherapy and 42 (0.8%) who received TCZ-IV
+csDMARDs had serious hypersensitivity events.
There was no clear impact of ADA development on safety,
regardless of TCZ administration as monotherapy or in combin-
ation with csDMARDs (table 2). Of the ﬁve patients who
received TCZ-IV monotherapy and developed ADAs, one had
clinically signiﬁcant hypersensitivity and none had serious
hypersensitivity or anaphylaxis. Of the 64 patients who received
TCZ-IV+csDMARDs and developed ADAs, 9 experienced clin-
ically signiﬁcant hypersensitivity and 6 had serious hypersensi-
tivity events, including the 5 anaphylaxis cases. Of the 12
patients who received TCZ-SC monotherapy and developed
ADAs, 1 had clinically signiﬁcant hypersensitivity and none had
serious hypersensitivity or anaphylaxis. Of the 35 patients who
received TCZ-SC+csDMARDs and developed ADAs, none
experienced anaphylaxis, serious hypersensitivity or clinically
signiﬁcant hypersensitivity.
ISRs were reported in 81 patients (13.1%) who received
TCZ-SC monotherapy compared with 229 (9.2%) who received
TCZ-SC+csDMARDs (table 2). One patient (0.2%) who
received TCZ-SC monotherapy and developed ADAs had an
ISR; three (0.1%) of the patients who received TCZ-SC
+csDMARDs and developed ADAs had ISRs.
Among all patients who developed ADAs with neutralising
potential following TCZ treatment, none experienced loss of
efﬁcacy, regardless of whether it was administered as monothe-
rapy or in combination with csDMARDs (table 2).
Table 1 Immunogenicity rates and safety and efficacy in patients who developed anti-TCZ antibodies following TCZ-SC or TCZ-IV treatment
TCZ-SC 162 mg qw or q2w
all-exposure (n=3099)
TCZ-IV 4 mg/kg or 8 mg/kg q4w
all-exposure (n=5875)
Anaphylaxis, n (%)* 0 10 (0.2)
Clinically significant hypersensitivity (leading to withdrawal), n (%)† 31 (1.0) 91 (1.5)
Serious hypersensitivity (reported as SAE), n (%)‡ 10 (0.3) 51 (0.9)
Injection-site reactions, n (%) 310 (10.0) N/A
Total patients screened for ADAs, n (%) 3094 (99.8) 5806 (98.8)
Total patients who developed ADAs, n (%)§ 47 (1.5) 69 (1.2)
Positive neutralisation assay, n (%)§¶ 40 (1.3) 54 (0.9)
Positive IgE assay, n (%)§ 9 (0.3) N/A
Anaphylaxis, n (%)*§ 0 5 (0.1)
Clinically significant hypersensitivity (leading to withdrawal), n (%)†§ 1 (0.03) 10 (0.2)
Serious hypersensitivity (reported as SAE), n (%)‡§ 0 6 (0.1)
Injection-site reactions, n (%)§ 4 (0.1) N/A
Loss of efficacy, n (%)§** 0 0
*Anaphylactic reactions were events that occurred during or within 24 hours of an infusion or injection and met Sampson criteria.
†Clinically significant hypersensitivity events were defined as any events that occurred during or within 24 hours of an infusion or injection and led to withdrawal from treatment.
‡Serious hypersensitivity events were defined as any events that occurred during or within 24 hours of an infusion or injection and were reported as SAEs.
§Denominator is total patients screened for ADAs.
¶The Fab assay was applied in the MUSASHI study to measure neutralisation potential.
**Loss of efficacy was defined as patients who withdrew from the study prematurely due to insufficient therapeutic response after experiencing an American College of Rheumatology
criteria for 50% improvement (ACR50) or European League Against Rheumatism good response.
ADA, antidrug antibody; N/A, not available; q2w, every other week; q4w, every 4 weeks; qw, every week; SAE, serious adverse event; TCZ, tocilizumab; TCZ-IV, intravenous TCZ; TCZ-SC,
subcutaneous TCZ.
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TCZ-washout samples
To minimise the potential TCZ interference in the immunogen-
icity assay, additional samples for ADA measurements were
obtained from the TCZ-SC versus TCZ-IV study20 at the
follow-up visits after treatment completion or after dosing inter-
ruption. In total, 928 samples were collected from 879 patients
(table 3). Among them, 549 samples (59.2%) from 503 patients
were TCZ-free (TCZ serum levels below the limit of quantita-
tion) and 239 samples (25.8%) from 238 patients had low TCZ
concentration (<10 μg/mL). Of the 503 patients who provided
TCZ-free samples, which allows for TCZ interference in the
immunogenicity assay to be excluded, only one patient (0.2%)
was positive for ADAs. Another two samples from two patients
who were positive for ADAs had TCZ concentrations of 0.2 μg/
mL and 18.1 μg/mL. All three patients who developed ADAs
did not experience hypersensitivity reactions or ISRs and did
not withdraw due to insufﬁcient therapeutic response or meet
the criteria for loss of efﬁcacy. None of the three patients who
were determined as ADA-positive in washout samples were posi-
tive at the regular sampling time points.
Immunogenicity in patients who missed doses
ADA development after dose interruption was analysed in three
TCZ-SC studies. In the TCZ-SC versus TCZ-IV study,31 179
patients from the TCZ-SC once-weekly (qw) group and 40
patients from the TCZ-IV-switch-to-TCZ-SC group missed ≥3
consecutive TCZ-SC qw injections, and 241 patients from the
TCZ-IV every-4-weeks and TCZ-SC-switch-to-TCZ-IV groups
missed ≥1 TCZ-IV infusion during the study; among these
patients, two in the TCZ-SC arm and two in the TCZ-IV arm
had negative screening assay results before the ﬁrst missed dose
and then were positive for conﬁrmation and neutralising assays
after dosing was resumed. In the TCZ-SC versus placebo
study,31 188 patients in the TCZ-SC every-other-week group
and 48 patients in the placebo-switch-to-TCZ-SC group missed
≥1 dose during the treatment period and had negative ADA
assays before the missed injection. One patient in the
placebo-switch-to-TCZ-SC arm was positive for ADAs by the
conﬁrmation and neutralising assays after dosing was resumed.
In the Japanese study,25 26 247 patients in the safety population
who received TCZ-SC had an injection interval of >21 days
between doses and were negative for ADAs prior to the dosing
interval. Among them, one patient in the TCZ-SC arm devel-
oped ADAs after reinitiating TCZ treatment. For all TCZ-SC
studies, no impact of ADAs on efﬁcacy or safety was observed in
patients who developed ADAs after dose interruption.
Pharmacokinetics
There was no obvious trend of reduced serum TCZ levels in the
patients who tested positive for ADAs, including those with neu-
tralising potential. A graphical analysis of apparent clearance
estimated by population PK analysis for patients with positive
Table 2 Safety, immunogenicity and effect of ADAs on safety and efficacy following TCZ as monotherapy or in combination with conventional
synthetic disease-modifying antirheumatic drugs (csDMARDs)
TCZ-SC mono 162 mg
qw or q2w (n=616)
TCZ-SC+csDMARDs 162 mg
qw or q2w (n=2483)
TCZ-IV mono 4 mg/kg or
8 mg/kg q4w (n=753)
TCZ-IV+csDMARDs 4 mg/kg
or 8 mg/kg q4w (n=5122)
Anaphylaxis, n (%)* 0 0 1 (0.1) 9 (0.2)
Clinically significant hypersensitivity (leading to
withdrawal), n (%)†
6 (1.0) 25 (1.0) 12 (1.6) 79 (1.5)
Serious hypersensitivity (reported as SAE), n (%)‡ 1 (0.2) 9 (0.4) 9 (1.2) 42 (0.8)
Injection-site reactions, n (%) 81 (13.1) 229 (9.2) N/A N/A
Total patients screened for ADAs, n (%) 615 (99.8) 2479 (99.8) 745 (98.9) 5061 (98.8)
Total patients who developed ADAs, n (%)§ 12 (2.0) 35 (1.4) 5 (0.7) 64 (1.3)
Positive neutralisation assay, n (%)§¶ 7 (1.1) 33 (1.3) 4 (0.5) 50 (1.0)
Positive IgE assay, n (%)§ 3 (0.5) 6 (0.2) N/A N/A
Anaphylaxis, n (%)*§ 0 0 0 5 (0.1)
Clinically significant hypersensitivity (leading to
withdrawal), n (%)†§
1 (0.2) 0 1 (0.1) 9 (0.2)
Serious hypersensitivity (reported as SAE), n (%)‡§ 0 0 0 6 (0.1)
Injection-site reactions, n (%)§ 1 (0.2) 3 (0.1) N/A N/A
Loss of efficacy, n (%)§** 0 0 0 0
*Anaphylactic reactions were events that occurred during or within 24 hours of an infusion or injection and met Sampson criteria.
†Clinically significant hypersensitivity events were defined as any events that occurred during or within 24 hours of an infusion or injection and led to withdrawal from treatment.
‡Serious hypersensitivity events were defined as any events that occurred during or within 24 hours of an infusion or injection and were reported as SAEs.
§Denominator is total patients screened for ADAs.
¶The Fab assay was applied in the MUSASHI study to measure neutralisation potential.
**Loss of efficacy was defined as patients who withdrew from the study prematurely due to insufficient therapeutic response after experiencing an American College of Rheumatology
criteria for 50% improvement (ACR50) or European League Against Rheumatism good response.
ADA, antidrug antibody; N/A, not available; q2w, every other week; q4w, every 4 weeks; qw, every week; SAE, serious adverse event; TCZ, tocilizumab; TCZ-IV, intravenous TCZ; TCZ-SC,
subcutaneous TCZ.
Table 3 TCZ-washout samples by TCZ concentration (SUMMACTA)
Total: 928 total samples from
879 patients TCZ BLQ TCZ <10 μg/mL TCZ ≥10 μg/mL
Washout samples, n (%)* 549 (59.2) 239 (25.8) 140 (15.1)
Patients, n 503 238 138
Total patients who developed
ADAs, n (%)†
1 (0.2) 1 (0.4) 1 (0.7)
Positive neutralisation assay† 0 0 1 (0.7)
Positive IgE assay 0 0 0
Note: Multiple samples (with different TCZ concentrations) could be provided by a
single patient.
*Denominator is total sample number.
†Denominator is total number of patients who provided washout samples.
ADA, antidrug antibody; BLQ, below the lower limit of quantitation (TCZ concentration,
100 ng/mL); TCZ, tocilizumab.
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ADA compared with patients with negative ADA status showed
no differences in intravenous studies (see online supplementary
ﬁgure S1) or SC studies (see online supplementary ﬁgure S2).
Moreover, no correlation was observed between relative ADA
concentration and TCZ values among ADA-positive patients in
the intravenous versus SC study (see online supplementary
ﬁgure S3).
In the TCZ-IV monotherapy versus TCZ-IV+MTX study in
patients with early RA, no overall trends of decreasing concen-
trations were noted for up to 2 years of treatment27 (in prepar-
ation/to be submitted). Similarly, in the TCZ-SC+csDMARDs
versus TCZ-IV+csDMARDs study, once steady state was
reached, mean TCZ concentrations in patients from both
groups remained stable up to week 97.21
DISCUSSION
Our pooled results from 8974 patients treated with TCZ indi-
cated that the incidence of ADA development was low, regard-
less of intravenous or SC formulation and whether it was
administered as monotherapy or in combination with
csDMARDs. In patients who did develop ADAs, ADAs were
mostly transient and no correlation to PK, safety events or loss
of efﬁcacy was observed. The precise mechanism of the
observed low immunogenicity in patients treated with TCZ has
not been fully elucidated; the immunogenic potential of a bio-
logic treatment is affected by several factors, including
molecule-related factors (eg, mechanisms of action, molecular
structure and manufacturing process) and patient characteristics.
ADA incidence is also dependent on the assay itself (eg, assay
sensitivity, speciﬁcity and methodology).
Immunogenicity assays are challenged and complicated by
drug interference, and the observed low incidence of ADA
might be a reﬂection of the assay used. To minimise TCZ inter-
ference, TCZ-washout samples were collected and evaluated in
the TCZ-SC versus TCZ-IV study.20 Among the 503 patients
who provided TCZ-free samples, the proportion who developed
ADAs was low (0.2%) across treatment arms, conﬁrming a low
incidence of ADA development when drug interference is ruled
out. Moreover, the observed low incidence of ADA develop-
ment is consistent with three independently published studies
that examined the immunogenicity of TCZ using commercially
available immunogenicity assays; in those studies, 0% to 3.3%
of patients treated with TCZ developed ADAs.32–34
One possible mechanism of the observed low immunogenicity
of TCZ might be related to the downregulation of B cell activi-
ties due to the blocking of IL-6 signalling (a different mecha-
nism of action from that of aTNFs). Our ﬁndings and a recent
study33 indicate no increased risk of ADA development and no
clear impact on TCZ trough level in either TCZ monotherapy
or combination therapy settings21 27 (in preparation/to be sub-
mitted). Consistently, similar efﬁcacy has been observed with
TCZ monotherapy compared with TCZ in combination with
csDMARDs (either intravenous or SC).35–38 In contrast, it has
been reported that with two aTNFs (adalimumab and inﬂixi-
mab), concomitant administration of MTX suppresses immuno-
genicity and maximises efﬁcacy.7 39 40 Development of ADAs
against adalimumab and inﬂiximab may correlate with the dis-
appearance of drug from the blood and may decrease efﬁcacy
by neutralising the drug or by creating immune complexes.10 41
In this study, patients who were positive for neutralising assay
did not experience a loss of efﬁcacy; it is possible that while the
neutralising antibodies were able to block TCZ in vitro, they
may not function as such in vivo (eg, are not at sufﬁcient con-
centration and/or afﬁnity) to affect TCZ levels or efﬁcacy. It is
unclear why in three patients, ADA became present after drug
washout, and the release of the inhibition of B cell activity after
TCZ washout leading to ADA development might be a possible
explanation; however, most of the detected anti-TCZ antibodies
were transient in this study.
Other possible factors contributing to low immunogenicity
might be molecule-related factors, including mAb structure (eg,
a speciﬁc molecular structure with an idiotype of low immuno-
genic potential) and manufacturing processes. In general, it is
not clear whether a humanised mAb treatment is more immuno-
genic than a fully human mAb. ADA development has been
reported for fully human mAbs (eg, adalimumab and golimu-
mab).42 ADAs against the fully human adalimumab induced
neutralising responses that varied by disease and therapy
(5–89%), and ADAs correlate with a lack of efﬁcacy in some
adalimumab-treated patients.7 41 43
To our knowledge, this study, including data from >8900
patients, is the most robust and comprehensive clinical trial-
based assessment addressing immunogenicity compared with
published data for a biologic RA treatment. In the small propor-
tion of patients who developed ADAs following administration
of TCZ-SC or TCZ-IV, no clear correlation of ADA develop-
ment to PK, clinical response or AEs was observed. Further,
administration of TCZ as monotherapy did not increase the risk
of immunogenicity and had no impact on the TCZ trough level.
However, the limitation due to the low number of ADA-positive
patients is acknowledged, especially between subgroups such as
TCZ monotherapy versus TCZ in combination with MTX.
Overall, our data suggest that routine ADA testing is unneces-
sary for the clinical use of TCZ in treating adult RA.
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